Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
98%
Graft-versus-host Disease (GvHD)
56%
Hematopoietic Cell Transplantation
52%
Marrow Transplantation
43%
Invasive Aspergillosis
42%
Haematopoietic Stem Cell Transplant Recipients
35%
Hematopoietic Stem Cell Transplantation
35%
Neutropenia
34%
Fungal Infection
34%
Cytomegalovirus
33%
Cytomegalovirus Infection
33%
Infectious Complications
30%
Confidence Interval
29%
Transplantation
28%
Antifungal Therapy
27%
Transplant Recipients
27%
Fever
26%
Risk Factors
25%
Bone Marrow Transplantation
25%
Infectious Diseases Society of America
23%
High Risk
22%
Invasive Fungal Infection
21%
Aspergillosis
21%
Pretransplant
20%
Infection Risk
20%
Bacterial Infection
20%
Hematopoietic Cell Transplant
20%
Hematological Malignancies
19%
Micafungin
19%
Amphotericin B
18%
Umbilical Cord Blood Transplantation
17%
Granulocyte Colony-stimulating Factor (G-CSF)
17%
Maribavir
17%
T Cell Depletion
16%
Neutropenic Patients
16%
Umbilical Cord Blood
16%
Myeloablative Conditioning
15%
Immunocompromised Patients
15%
Unrelated Donor
15%
Bloodstream Infection
15%
Randomized Double-blind
15%
Allogeneic Transplantation
15%
Fluconazole
15%
Vaccination
15%
Posaconazole
14%
Aspergillus Infection
14%
Hematopoietic Stem Cell Transplant
14%
Marrow
14%
BK Polyomavirus (BKPyV)
14%
United States
14%
Medicine and Dentistry
Infection
100%
Hematopoietic Cell
83%
Cell Transplantation
60%
Hematopoietic Stem Cell Transplantation
35%
Mycosis
30%
Cytomegalovirus
29%
Invasive Aspergillosis
28%
Infectious Disease
25%
Graft Versus Host Reaction
25%
Neutropenia
24%
Aspergillosis
24%
Bloodstream Infection
23%
Diseases
23%
Cytomegalovirus Infection
23%
Bone Marrow Transplantation
20%
Infectious Complication
20%
Allograft
18%
Placebo
17%
Clinical Trial
17%
Antiinfective Agent
17%
Antifungal Therapy
16%
Pediatrics
16%
Hematologic Malignancy
15%
Cord Blood
15%
Cohort Effect
15%
BK Virus
14%
Bacterial Infection
14%
Patient Population
13%
Viremia
12%
Kidney Graft
11%
Pathogen
11%
Immunosuppressive Treatment
11%
Adverse Event
11%
Cell-Free DNA
10%
Systemic Mycosis
10%
Varicella Zoster Vaccine
10%
Malignant Neoplasm
10%
Immunocompromised Patient
10%
Engraftment
10%
Aspergillus
10%
Human Immunodeficiency Virus
9%
Ganciclovir
9%
Cord Blood Stem Cell Transplantation
9%
Acute Graft Versus Host Disease
9%
Amphotericin B
9%
Virus Infection
9%
Micafungin
9%
Immune Reconstitution
8%
T Cell
8%
Vancomycin Resistant Enterococcus
8%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
77%
Diseases
49%
Invasive Aspergillosis
39%
Neutropenia
33%
Mycosis
32%
Bloodstream Infection
24%
Clinical Trial
23%
Placebo
21%
Graft Versus Host Reaction
20%
Amphotericin B
20%
Cytomegalovirus Infection
19%
Malignant Neoplasm
19%
BK Virus
18%
Adverse Event
17%
Micafungin
17%
Bacterial Infection
17%
Antiinfective Agent
16%
Antifungal Therapy
16%
Cytomegalovirus
16%
Hematologic Malignancy
15%
Systemic Mycosis
14%
Fluconazole
13%
Posaconazole
13%
Ganciclovir
13%
Virus Infection
13%
Benzimidavir
13%
Infectious Agent
13%
Aspergillosis
11%
Infectious Complication
11%
Immunocompromised Patient
11%
Candida Albicans
10%
Varicella Zoster Vaccine
10%
Viremia
10%
Invasive Candidiasis
9%
Caspofungin
9%
Acute Leukemia
8%
Zygomycosis
8%
Mucormycosis
8%
Granulocyte Colony Stimulating Factor
8%
Open-Label Trial
8%
Vancomycin-Resistant Enterococcus
8%
Vancomycin
8%
Recurrent Disease
8%
Antibiotics
8%
Kidney Disease
7%
Chemotherapy
7%
Antimicrobial Resistance
7%
Aspergillus
7%
Myelodysplastic Syndrome
7%
Cyclophosphamide
6%
